Calithera Biosciences, Inc.: Business Overview, Financials & Competitive Analysis
Calithera Biosciences, Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Shell company in advanced liquidation with negligible investor appeal; primarily of interest only for asset sale potential or shell reorganization opportunities. Company is in liquidation phase with minimal market value (~$974) and no revenue generation. Stock trades at $0.0002 on OTC markets with extremely thin liquidity. No active business.
What is Calithera Biosciences, Inc.'s industry? Calithera Biosciences, Inc. (calithera.com) operates in Biopharmaceuticals (Liquidated/Shell Company Status). AskCyborg classifies Calithera Biosciences, Inc. under Biopharmaceuticals (Liquidated/Shell Company Status) in its company registry.
Calithera Biosciences operates under a plan of liquidation approved in January 2023 and was previously engaged in clinical stage precision oncology biopharmaceutical business. The company is winding up its operations ...
Cyborg Score thesis
Shell company in advanced liquidation with negligible investor appeal; primarily of interest only for asset sale potential or...
Read the full analyst-debate transcript →Get the Latest Calithera Biosciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCalithera Biosciences, Inc. Overview
Pro stress-test →Calithera Biosciences operates under a plan of liquidation approved in January 2023 and was previously engaged in clinical stage precision oncology biopharmaceutical business. The company is winding up its operations and seeking to sell all of its clinical assets and programs.
Strategic Profile
Pro stress-test →The company was focused on discovery and development of small molecule inhibitors targeting metabolic pathways critical to cancer cell growth, aiming to create novel therapeutic options for solid tumors and hematologic malignancies. The company has not generated any revenue.
Competitive Landscape
Pro stress-test →Company is no longer a competitive participant in the oncology metabolic pathway inhibitor space. Historical competitors included other precision oncology firms developing tumor metabolism-targeting therapies, but Calithera has exited the competitive market through liquidation.
Industry Context
Calithera Biosciences, Inc. operates in Biopharmaceuticals (Liquidated/Shell Company Status).
Key facts
Founded: 2010 · Headquarters: South San Francisco, California · Revenue: $0 · Market cap: $974